The Mumbai based Wockhardt has received US FDA approval to market ceftazidime injections containing 1 gm/vial, the generic version of GlaxoSmithKline's Fortaz. Ceftazidime is used for treating various kinds of infections. Wockhardt is expected to launch the product in the US market shortly.
The details can be read here.
No comments:
Post a Comment